EudraCT Number: 2004-000572-14 Sponsor Protocol Number: EFC6088 (XRP9881B/2001) Start Date: 2004-10-08
Sponsor Name: Aventis Pharmaceuticals, Inc. (a subsidiary of sanofi-aventis group)
Full Title: Phase II multicenter, open label, non-randomized study of intravenous RPR109881 q 3 weeks in patients with metastatic breast cancer progressing after therapy with anthracyclines, taxanes, and capec...
Medical condition: Metastatic breast cancer patients after failure to anthracyclines, taxanes and capecitabine.
Disease: Version SOC Term Classification Code Term Level
10055113
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: DK (Completed) IT (Completed) ES (Ongoing) BE (Completed)
Trial results: View results

EudraCT Number: 2004-000587-26 Sponsor Protocol Number: CFTY720A2218E1 Start Date: 2005-02-01
Sponsor Name: Novartis Pharma Services AG
Full Title: A 24-month Extension to a one-year, multicentre, double-blinded, double-dummy, randomized study to evaluate the safety and efficacy of two doses of FTY720 combined with full-dose Neoral and steroid...
Medical condition: Prophylaxis of kidney allograft rejection in de novo adult renal transplant recipients
Disease: Version SOC Term Classification Code Term Level
7.0 10023439 LLT
Population Age: Adults Gender: Male, Female
Trial protocol: HU (Completed) DE (Completed) IT (Completed)
Trial results: View results
EudraCT Number: 2004-000596-34 Sponsor Protocol Number: WX17798 Start Date: 2005-05-19
Sponsor Name: F.Hoffmann-La Roche Ltd.
Full Title: A prospective, randomized, double-blind, placebo controlled, parallel group, multicenter, 36-weeks trial to assess the efficacy and safety of adjunct mycophenolate mofetil (MMF) to maintain or impr...
Medical condition: Myasthenia gravis
Disease: Version SOC Term Classification Code Term Level
7.1 10028417 LLT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: CZ (Completed) HU (Completed) IT (Completed) ES (Ongoing)
Trial results: View results

EudraCT Number: 2004-000835-27 Sponsor Protocol Number: NW-1015/017/III/2003 Start Date: 2004-12-03
Sponsor Name: NEWRON PHARMACEUTICALS
Full Title: A phase III, double-blind, placebo-controlled, 12-month extension study to investigate the efficacy and safety of a dose range of safinamide of 50-200 mg/day, as add-on therapy in patients with ear...
Medical condition: Parkinson's Disease
Disease: Version SOC Term Classification Code Term Level
6.1 10061536 PT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: IT (Completed) ES (Ongoing)
Trial results: (No results available)
EudraCT Number: 2004-000851-41 Sponsor Protocol Number: DRI5029 Start Date: 2004-10-04
Sponsor Name: Sanofi-Synthelabo AB
Full Title: A randomized, double-blind, placebo-controlled, parallel-group, fixed-dose, multicenter study evaluating the efficacy and safety of four doses of SR147778 in obese patients
Medical condition: Obesity is becoming a major health problem in western societies. Its prevalence is increasing especially in USA, UK, and Germany. Obesity is responsible for increased morbidity and mortality. The c...
Disease: Version SOC Term Classification Code Term Level
7.0 10029883 LLT
Population Age: Adults Gender: Male, Female
Trial protocol: FI (Completed) ES (Ongoing)
Trial results: View results

EudraCT Number: 2005-000006-32 Sponsor Protocol Number: IXR-203-30-204 Start Date: 2005-06-13
Sponsor Name: IVAX RESEARCH, INC.
Full Title: A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, DOSE RANGING STUDY TO DETERMINE THE EFFICACY AND SAFETY OF AN INVESTIGATIONAL INTRANASAL CORTICOSTEROID COMPARED TO PLACEBO AND OPEN-LABEL FLUTICASONE PR...
Medical condition: Perennial (persistant) Allergic Rhinitis
Disease: Version SOC Term Classification Code Term Level
Population Age: Children, Under 18 Gender: Male, Female
Trial protocol: SK (Ongoing)
Trial results: (No results available)
EudraCT Number: 2005-000021-32 Sponsor Protocol Number: H3E-MC-S080 Start Date: 2005-07-11
Sponsor Name: Eli Lilly and Company Limited
Full Title: A Randomized Phase 2 Trial of Doxorubicin plus Pemetrexed followed by Docetaxel, versus Doxorubicin plus Cyclophosphamide followed by Docetaxel, as Neoadjuvant Treatment for Early Breast Cancer
Medical condition: Females with histologically confirmed diagnosis of primary early breast cancer, with a tumor size ≥ 2 cm, of Stages T2-T4/N0-2/, as confirmed by incisional or core biopsy M0 will be treated with ch...
Disease: Version SOC Term Classification Code Term Level
Population Age: Adults, Elderly Gender: Female
Trial protocol: DE (Completed) ES (Ongoing) IT (Completed)
Trial results: View results

EudraCT Number: 2005-000043-28 Sponsor Protocol Number: E05-001 Start Date: 2005-04-19
Sponsor Name: ALEXION PHARMACEUTICALS INCORPORATED
Full Title: A Phase III, Open-Label, Extension Study of Eculizumab in Patients with Transfusion Dependent, Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Participated in the TRIUMPH (C04-001), SH...
Medical condition: paroxysmal nocturnal hemoglobinuria
Disease: Version SOC Term Classification Code Term Level
7.0 10034042 PT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: GB (Completed) IE (Completed) SE (Completed) DE (Completed) ES (Completed) IT (Completed)
Trial results: View results
EudraCT Number: 2005-000048-10 Sponsor Protocol Number: CCAD106A2101 Start Date: 2005-04-20
Sponsor Name: Novartis Pharma Services AG
Full Title: A 52-week, multi-center, randomized, double-blind, placebo-controlled, time-lagged, parallel group study in patients with mild to moderate Alzheimer's Disease (AD) to investigate the safety, tolera...
Medical condition: Alzheimer's disease
Disease: Version SOC Term Classification Code Term Level
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: SE (Completed)
Trial results: View results

EudraCT Number: 2005-000049-12 Sponsor Protocol Number: STH13889 Start Date: 2005-03-07
Sponsor Name: Sheffield teaching Hospitals NHS Foundation Trust
Full Title: The effects of testosterone therapy in men with pulmonary hypertension
Medical condition: Pulmonary Hypertension
Disease: Version SOC Term Classification Code Term Level
Population Age: Adults, Elderly Gender: Male
Trial protocol: GB (Completed)
Trial results: View results